0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Pril-series Drugs API Market Research Report 2026
Published Date: 2026-04-15
|
Report Code: QYRE-Auto-15O17314
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Pril series Drugs API Market Research Report 2024
BUY CHAPTERS

Global Pril-series Drugs API Market Research Report 2026

Code: QYRE-Auto-15O17314
Report
2026-04-15
Pages:126
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Pril-series Drugs API Market

The global Pril-series Drugs API market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Pril-series Drugs API competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Pril-series drugs are one of the commonly used antihypertensive drugs in clinical practice, ending with "Pril", such as perindopril and enalapril. Pril-series drugs are called Angiotensin-converting enzyme (ACE) inhibitors, are medicines that help relax the veins and arteries to lower blood pressure.
The North American market for Pril-series Drugs API is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Pril-series Drugs API is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Pril-series Drugs API include Huahai Pharmaceutical, Zhejiang Changming Pharmaceutical, Dr. Reddy's Laboratories, Glenmark, ScinoPharm, Novartis Pharma, Sun Pharmaceutical, Farmhispania, Medichem, Hetero, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Pril-series Drugs API market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Pril-series Drugs API. The Pril-series Drugs API market size, estimates, and forecasts are provided in terms of sales volume (Tons) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Pril-series Drugs API market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Pril-series Drugs API manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Pril-series Drugs API Market Report

Report Metric Details
Report Name Pril-series Drugs API Market
Segment by Type
  • Enalapril
  • Lisinopril
  • Captopril
  • Ramipril
  • Perindopril
  • Benazepril
  • Others
by Application
  • Tablets
  • Capsules
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Huahai Pharmaceutical, Zhejiang Changming Pharmaceutical, Dr. Reddy's Laboratories, Glenmark, ScinoPharm, Novartis Pharma, Sun Pharmaceutical, Farmhispania, Medichem, Hetero, Siegfried Evionnaz, Changzhou Pharmaceutical Factory, Chongqing Southwest No. 2 Pharmaceutical Factory, Ningbo Menovo Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Pril-series Drugs API manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Pril-series Drugs API sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Pril-series Drugs API Market report?

Ans: The main players in the Pril-series Drugs API Market are Huahai Pharmaceutical, Zhejiang Changming Pharmaceutical, Dr. Reddy's Laboratories, Glenmark, ScinoPharm, Novartis Pharma, Sun Pharmaceutical, Farmhispania, Medichem, Hetero, Siegfried Evionnaz, Changzhou Pharmaceutical Factory, Chongqing Southwest No. 2 Pharmaceutical Factory, Ningbo Menovo Pharmaceutical

What are the Application segmentation covered in the Pril-series Drugs API Market report?

Ans: The Applications covered in the Pril-series Drugs API Market report are Tablets, Capsules, Others

What are the Type segmentation covered in the Pril-series Drugs API Market report?

Ans: The Types covered in the Pril-series Drugs API Market report are Enalapril, Lisinopril, Captopril, Ramipril, Perindopril, Benazepril, Others

1 Pril-series Drugs API Market Overview
1.1 Product Definition
1.2 Pril-series Drugs API by Type
1.2.1 Global Pril-series Drugs API Market Value by Type: 2025 vs 2032
1.2.2 Enalapril
1.2.3 Lisinopril
1.2.4 Captopril
1.2.5 Ramipril
1.2.6 Perindopril
1.2.7 Benazepril
1.2.8 Others
1.3 Pril-series Drugs API by Application
1.3.1 Global Pril-series Drugs API Market Value by Application: 2025 vs 2032
1.3.2 Tablets
1.3.3 Capsules
1.3.4 Others
1.4 Global Pril-series Drugs API Market Size Estimates and Forecasts
1.4.1 Global Pril-series Drugs API Revenue 2021–2032
1.4.2 Global Pril-series Drugs API Sales 2021–2032
1.4.3 Global Pril-series Drugs API Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Pril-series Drugs API Market Competition by Manufacturers
2.1 Global Pril-series Drugs API Sales Market Share by Manufacturers (2021–2026)
2.2 Global Pril-series Drugs API Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Pril-series Drugs API Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Pril-series Drugs API, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Pril-series Drugs API, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Pril-series Drugs API, Product Types and Applications
2.7 Global Key Manufacturers of Pril-series Drugs API, Date of Entry into the Industry
2.8 Global Pril-series Drugs API Market Competitive Situation and Trends
2.8.1 Global Pril-series Drugs API Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Pril-series Drugs API Players Market Share by Revenue
2.8.3 Global Pril-series Drugs API Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Pril-series Drugs API Market Scenario by Region
3.1 Global Pril-series Drugs API Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Pril-series Drugs API Sales by Region: 2021–2032
3.2.1 Global Pril-series Drugs API Sales by Region: 2021–2026
3.2.2 Global Pril-series Drugs API Sales by Region: 2027–2032
3.3 Global Pril-series Drugs API Revenue by Region: 2021–2032
3.3.1 Global Pril-series Drugs API Revenue by Region: 2021–2026
3.3.2 Global Pril-series Drugs API Revenue by Region: 2027–2032
3.4 North America Pril-series Drugs API Market Facts & Figures by Country
3.4.1 North America Pril-series Drugs API Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Pril-series Drugs API Sales by Country (2021–2032)
3.4.3 North America Pril-series Drugs API Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Pril-series Drugs API Market Facts & Figures by Country
3.5.1 Europe Pril-series Drugs API Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Pril-series Drugs API Sales by Country (2021–2032)
3.5.3 Europe Pril-series Drugs API Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pril-series Drugs API Market Facts & Figures by Region
3.6.1 Asia Pacific Pril-series Drugs API Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Pril-series Drugs API Sales by Region (2021–2032)
3.6.3 Asia Pacific Pril-series Drugs API Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Pril-series Drugs API Market Facts & Figures by Country
3.7.1 Latin America Pril-series Drugs API Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Pril-series Drugs API Sales by Country (2021–2032)
3.7.3 Latin America Pril-series Drugs API Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Pril-series Drugs API Market Facts & Figures by Country
3.8.1 Middle East and Africa Pril-series Drugs API Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Pril-series Drugs API Sales by Country (2021–2032)
3.8.3 Middle East and Africa Pril-series Drugs API Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Pril-series Drugs API Sales by Type (2021–2032)
4.1.1 Global Pril-series Drugs API Sales by Type (2021–2026)
4.1.2 Global Pril-series Drugs API Sales by Type (2027–2032)
4.1.3 Global Pril-series Drugs API Sales Market Share by Type (2021–2032)
4.2 Global Pril-series Drugs API Revenue by Type (2021–2032)
4.2.1 Global Pril-series Drugs API Revenue by Type (2021–2026)
4.2.2 Global Pril-series Drugs API Revenue by Type (2027–2032)
4.2.3 Global Pril-series Drugs API Revenue Market Share by Type (2021–2032)
4.3 Global Pril-series Drugs API Price by Type (2021–2032)
5 Segment by Application
5.1 Global Pril-series Drugs API Sales by Application (2021–2032)
5.1.1 Global Pril-series Drugs API Sales by Application (2021–2026)
5.1.2 Global Pril-series Drugs API Sales by Application (2027–2032)
5.1.3 Global Pril-series Drugs API Sales Market Share by Application (2021–2032)
5.2 Global Pril-series Drugs API Revenue by Application (2021–2032)
5.2.1 Global Pril-series Drugs API Revenue by Application (2021–2026)
5.2.2 Global Pril-series Drugs API Revenue by Application (2027–2032)
5.2.3 Global Pril-series Drugs API Revenue Market Share by Application (2021–2032)
5.3 Global Pril-series Drugs API Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Huahai Pharmaceutical
6.1.1 Huahai Pharmaceutical Company Information
6.1.2 Huahai Pharmaceutical Description and Business Overview
6.1.3 Huahai Pharmaceutical Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Huahai Pharmaceutical Pril-series Drugs API Product Portfolio
6.1.5 Huahai Pharmaceutical Recent Developments/Updates
6.2 Zhejiang Changming Pharmaceutical
6.2.1 Zhejiang Changming Pharmaceutical Company Information
6.2.2 Zhejiang Changming Pharmaceutical Description and Business Overview
6.2.3 Zhejiang Changming Pharmaceutical Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Zhejiang Changming Pharmaceutical Pril-series Drugs API Product Portfolio
6.2.5 Zhejiang Changming Pharmaceutical Recent Developments/Updates
6.3 Dr. Reddy's Laboratories
6.3.1 Dr. Reddy's Laboratories Company Information
6.3.2 Dr. Reddy's Laboratories Description and Business Overview
6.3.3 Dr. Reddy's Laboratories Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Dr. Reddy's Laboratories Pril-series Drugs API Product Portfolio
6.3.5 Dr. Reddy's Laboratories Recent Developments/Updates
6.4 Glenmark
6.4.1 Glenmark Company Information
6.4.2 Glenmark Description and Business Overview
6.4.3 Glenmark Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Glenmark Pril-series Drugs API Product Portfolio
6.4.5 Glenmark Recent Developments/Updates
6.5 ScinoPharm
6.5.1 ScinoPharm Company Information
6.5.2 ScinoPharm Description and Business Overview
6.5.3 ScinoPharm Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 ScinoPharm Pril-series Drugs API Product Portfolio
6.5.5 ScinoPharm Recent Developments/Updates
6.6 Novartis Pharma
6.6.1 Novartis Pharma Company Information
6.6.2 Novartis Pharma Description and Business Overview
6.6.3 Novartis Pharma Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Novartis Pharma Pril-series Drugs API Product Portfolio
6.6.5 Novartis Pharma Recent Developments/Updates
6.7 Sun Pharmaceutical
6.7.1 Sun Pharmaceutical Company Information
6.7.2 Sun Pharmaceutical Description and Business Overview
6.7.3 Sun Pharmaceutical Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Sun Pharmaceutical Pril-series Drugs API Product Portfolio
6.7.5 Sun Pharmaceutical Recent Developments/Updates
6.8 Farmhispania
6.8.1 Farmhispania Company Information
6.8.2 Farmhispania Description and Business Overview
6.8.3 Farmhispania Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Farmhispania Pril-series Drugs API Product Portfolio
6.8.5 Farmhispania Recent Developments/Updates
6.9 Medichem
6.9.1 Medichem Company Information
6.9.2 Medichem Description and Business Overview
6.9.3 Medichem Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Medichem Pril-series Drugs API Product Portfolio
6.9.5 Medichem Recent Developments/Updates
6.10 Hetero
6.10.1 Hetero Company Information
6.10.2 Hetero Description and Business Overview
6.10.3 Hetero Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Hetero Pril-series Drugs API Product Portfolio
6.10.5 Hetero Recent Developments/Updates
6.11 Siegfried Evionnaz
6.11.1 Siegfried Evionnaz Company Information
6.11.2 Siegfried Evionnaz Description and Business Overview
6.11.3 Siegfried Evionnaz Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Siegfried Evionnaz Pril-series Drugs API Product Portfolio
6.11.5 Siegfried Evionnaz Recent Developments/Updates
6.12 Changzhou Pharmaceutical Factory
6.12.1 Changzhou Pharmaceutical Factory Company Information
6.12.2 Changzhou Pharmaceutical Factory Description and Business Overview
6.12.3 Changzhou Pharmaceutical Factory Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Changzhou Pharmaceutical Factory Pril-series Drugs API Product Portfolio
6.12.5 Changzhou Pharmaceutical Factory Recent Developments/Updates
6.13 Chongqing Southwest No. 2 Pharmaceutical Factory
6.13.1 Chongqing Southwest No. 2 Pharmaceutical Factory Company Information
6.13.2 Chongqing Southwest No. 2 Pharmaceutical Factory Description and Business Overview
6.13.3 Chongqing Southwest No. 2 Pharmaceutical Factory Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Chongqing Southwest No. 2 Pharmaceutical Factory Pril-series Drugs API Product Portfolio
6.13.5 Chongqing Southwest No. 2 Pharmaceutical Factory Recent Developments/Updates
6.14 Ningbo Menovo Pharmaceutical
6.14.1 Ningbo Menovo Pharmaceutical Company Information
6.14.2 Ningbo Menovo Pharmaceutical Description and Business Overview
6.14.3 Ningbo Menovo Pharmaceutical Pril-series Drugs API Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Ningbo Menovo Pharmaceutical Pril-series Drugs API Product Portfolio
6.14.5 Ningbo Menovo Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pril-series Drugs API Industry Chain Analysis
7.2 Pril-series Drugs API Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pril-series Drugs API Production Mode & Process Analysis
7.4 Pril-series Drugs API Sales and Marketing
7.4.1 Pril-series Drugs API Sales Channels
7.4.2 Pril-series Drugs API Distributors
7.5 Pril-series Drugs API Customer Analysis
8 Pril-series Drugs API Market Dynamics
8.1 Pril-series Drugs API Industry Trends
8.2 Pril-series Drugs API Market Drivers
8.3 Pril-series Drugs API Market Challenges
8.4 Pril-series Drugs API Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Pril-series Drugs API Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Pril-series Drugs API Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Pril-series Drugs API Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Pril-series Drugs API Sales (Tons) of Key Manufacturers (2021–2026)
 Table 5. Global Pril-series Drugs API Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Pril-series Drugs API Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Pril-series Drugs API Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Pril-series Drugs API Average Price (US$/Kg) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Pril-series Drugs API, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Pril-series Drugs API, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Pril-series Drugs API, Product Types and Applications
 Table 12. Global Key Manufacturers of Pril-series Drugs API, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Pril-series Drugs API Companies by Tier (Tier 1, Tier 2, Tier 3), based on Pril-series Drugs API Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Pril-series Drugs API Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Pril-series Drugs API Sales by Region (Tons), 2021–2026
 Table 18. Global Pril-series Drugs API Sales Market Share by Region (2021–2026)
 Table 19. Global Pril-series Drugs API Sales by Region (Tons), 2027–2032
 Table 20. Global Pril-series Drugs API Sales Market Share by Region (2027–2032)
 Table 21. Global Pril-series Drugs API Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Pril-series Drugs API Revenue Market Share by Region (2021–2026)
 Table 23. Global Pril-series Drugs API Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Pril-series Drugs API Revenue Market Share by Region (2027–2032)
 Table 25. North America Pril-series Drugs API Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Pril-series Drugs API Sales by Country (Tons), 2021–2026
 Table 27. North America Pril-series Drugs API Sales by Country (Tons), 2027–2032
 Table 28. North America Pril-series Drugs API Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Pril-series Drugs API Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Pril-series Drugs API Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Pril-series Drugs API Sales by Country (Tons), 2021–2026
 Table 32. Europe Pril-series Drugs API Sales by Country (Tons), 2027–2032
 Table 33. Europe Pril-series Drugs API Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Pril-series Drugs API Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Pril-series Drugs API Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Pril-series Drugs API Sales by Region (Tons), 2021–2026
 Table 37. Asia Pacific Pril-series Drugs API Sales by Region (Tons), 2027–2032
 Table 38. Asia Pacific Pril-series Drugs API Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Pril-series Drugs API Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Pril-series Drugs API Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Pril-series Drugs API Sales by Country (Tons), 2021–2026
 Table 42. Latin America Pril-series Drugs API Sales by Country (Tons), 2027–2032
 Table 43. Latin America Pril-series Drugs API Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Pril-series Drugs API Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Pril-series Drugs API Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Pril-series Drugs API Sales by Country (Tons), 2021–2026
 Table 47. Middle East and Africa Pril-series Drugs API Sales by Country (Tons), 2027–2032
 Table 48. Middle East and Africa Pril-series Drugs API Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Pril-series Drugs API Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Pril-series Drugs API Sales (Tons) by Type (2021–2026)
 Table 51. Global Pril-series Drugs API Sales (Tons) by Type (2027–2032)
 Table 52. Global Pril-series Drugs API Sales Market Share by Type (2021–2026)
 Table 53. Global Pril-series Drugs API Sales Market Share by Type (2027–2032)
 Table 54. Global Pril-series Drugs API Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Pril-series Drugs API Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Pril-series Drugs API Revenue Market Share by Type (2021–2026)
 Table 57. Global Pril-series Drugs API Revenue Market Share by Type (2027–2032)
 Table 58. Global Pril-series Drugs API Price (US$/Kg) by Type (2021–2026)
 Table 59. Global Pril-series Drugs API Price (US$/Kg) by Type (2027–2032)
 Table 60. Global Pril-series Drugs API Sales (Tons) by Application (2021–2026)
 Table 61. Global Pril-series Drugs API Sales (Tons) by Application (2027–2032)
 Table 62. Global Pril-series Drugs API Sales Market Share by Application (2021–2026)
 Table 63. Global Pril-series Drugs API Sales Market Share by Application (2027–2032)
 Table 64. Global Pril-series Drugs API Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Pril-series Drugs API Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Pril-series Drugs API Revenue Market Share by Application (2021–2026)
 Table 67. Global Pril-series Drugs API Revenue Market Share by Application (2027–2032)
 Table 68. Global Pril-series Drugs API Price (US$/Kg) by Application (2021–2026)
 Table 69. Global Pril-series Drugs API Price (US$/Kg) by Application (2027–2032)
 Table 70. Huahai Pharmaceutical Company Information
 Table 71. Huahai Pharmaceutical Description and Business Overview
 Table 72. Huahai Pharmaceutical Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 73. Huahai Pharmaceutical Pril-series Drugs API Product
 Table 74. Huahai Pharmaceutical Recent Developments/Updates
 Table 75. Zhejiang Changming Pharmaceutical Company Information
 Table 76. Zhejiang Changming Pharmaceutical Description and Business Overview
 Table 77. Zhejiang Changming Pharmaceutical Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 78. Zhejiang Changming Pharmaceutical Pril-series Drugs API Product
 Table 79. Zhejiang Changming Pharmaceutical Recent Developments/Updates
 Table 80. Dr. Reddy's Laboratories Company Information
 Table 81. Dr. Reddy's Laboratories Description and Business Overview
 Table 82. Dr. Reddy's Laboratories Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 83. Dr. Reddy's Laboratories Pril-series Drugs API Product
 Table 84. Dr. Reddy's Laboratories Recent Developments/Updates
 Table 85. Glenmark Company Information
 Table 86. Glenmark Description and Business Overview
 Table 87. Glenmark Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 88. Glenmark Pril-series Drugs API Product
 Table 89. Glenmark Recent Developments/Updates
 Table 90. ScinoPharm Company Information
 Table 91. ScinoPharm Description and Business Overview
 Table 92. ScinoPharm Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 93. ScinoPharm Pril-series Drugs API Product
 Table 94. ScinoPharm Recent Developments/Updates
 Table 95. Novartis Pharma Company Information
 Table 96. Novartis Pharma Description and Business Overview
 Table 97. Novartis Pharma Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 98. Novartis Pharma Pril-series Drugs API Product
 Table 99. Novartis Pharma Recent Developments/Updates
 Table 100. Sun Pharmaceutical Company Information
 Table 101. Sun Pharmaceutical Description and Business Overview
 Table 102. Sun Pharmaceutical Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 103. Sun Pharmaceutical Pril-series Drugs API Product
 Table 104. Sun Pharmaceutical Recent Developments/Updates
 Table 105. Farmhispania Company Information
 Table 106. Farmhispania Description and Business Overview
 Table 107. Farmhispania Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 108. Farmhispania Pril-series Drugs API Product
 Table 109. Farmhispania Recent Developments/Updates
 Table 110. Medichem Company Information
 Table 111. Medichem Description and Business Overview
 Table 112. Medichem Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 113. Medichem Pril-series Drugs API Product
 Table 114. Medichem Recent Developments/Updates
 Table 115. Hetero Company Information
 Table 116. Hetero Description and Business Overview
 Table 117. Hetero Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 118. Hetero Pril-series Drugs API Product
 Table 119. Hetero Recent Developments/Updates
 Table 120. Siegfried Evionnaz Company Information
 Table 121. Siegfried Evionnaz Description and Business Overview
 Table 122. Siegfried Evionnaz Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 123. Siegfried Evionnaz Pril-series Drugs API Product
 Table 124. Siegfried Evionnaz Recent Developments/Updates
 Table 125. Changzhou Pharmaceutical Factory Company Information
 Table 126. Changzhou Pharmaceutical Factory Description and Business Overview
 Table 127. Changzhou Pharmaceutical Factory Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 128. Changzhou Pharmaceutical Factory Pril-series Drugs API Product
 Table 129. Changzhou Pharmaceutical Factory Recent Developments/Updates
 Table 130. Chongqing Southwest No. 2 Pharmaceutical Factory Company Information
 Table 131. Chongqing Southwest No. 2 Pharmaceutical Factory Description and Business Overview
 Table 132. Chongqing Southwest No. 2 Pharmaceutical Factory Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 133. Chongqing Southwest No. 2 Pharmaceutical Factory Pril-series Drugs API Product
 Table 134. Chongqing Southwest No. 2 Pharmaceutical Factory Recent Developments/Updates
 Table 135. Ningbo Menovo Pharmaceutical Company Information
 Table 136. Ningbo Menovo Pharmaceutical Description and Business Overview
 Table 137. Ningbo Menovo Pharmaceutical Pril-series Drugs API Sales (Tons), Revenue (US$ Million), Price (US$/Kg), and Gross Margin (2021–2026)
 Table 138. Ningbo Menovo Pharmaceutical Pril-series Drugs API Product
 Table 139. Ningbo Menovo Pharmaceutical Recent Developments/Updates
 Table 140. Key Raw Materials Lists
 Table 141. Raw Materials Key Suppliers Lists
 Table 142. Pril-series Drugs API Distributors List
 Table 143. Pril-series Drugs API Customers List
 Table 144. Pril-series Drugs API Market Trends
 Table 145. Pril-series Drugs API Market Drivers
 Table 146. Pril-series Drugs API Market Challenges
 Table 147. Pril-series Drugs API Market Restraints
 Table 148. Research Programs/Design for This Report
 Table 149. Key Data Information from Secondary Sources
 Table 150. Key Data Information from Primary Sources
 Table 151. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Pril-series Drugs API
 Figure 2. Global Pril-series Drugs API Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Pril-series Drugs API Market Share by Type: 2025 & 2032
 Figure 4. Enalapril Product Picture
 Figure 5. Lisinopril Product Picture
 Figure 6. Captopril Product Picture
 Figure 7. Ramipril Product Picture
 Figure 8. Perindopril Product Picture
 Figure 9. Benazepril Product Picture
 Figure 10. Others Product Picture
 Figure 11. Global Pril-series Drugs API Market Value by Application (US$ Million), 2021–2032
 Figure 12. Global Pril-series Drugs API Market Share by Application: 2025 & 2032
 Figure 13. Tablets
 Figure 14. Capsules
 Figure 15. Others
 Figure 16. Global Pril-series Drugs API Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 17. Global Pril-series Drugs API Market Size (US$ Million), 2021–2032
 Figure 18. Global Pril-series Drugs API Sales (Tons), 2021–2032
 Figure 19. Global Pril-series Drugs API Average Price (US$/Kg), 2021–2032
 Figure 20. Pril-series Drugs API Report Years Considered
 Figure 21. Pril-series Drugs API Sales Share by Manufacturers in 2025
 Figure 22. Global Pril-series Drugs API Revenue Share by Manufacturers in 2025
 Figure 23. Top 5 and Top 10 Global Pril-series Drugs API Players: Market Share by Revenue in Pril-series Drugs API in 2025
 Figure 24. Pril-series Drugs API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 25. Global Pril-series Drugs API Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 26. North America Pril-series Drugs API Sales Market Share by Country (2021–2032)
 Figure 27. North America Pril-series Drugs API Revenue Market Share by Country (2021–2032)
 Figure 28. United States Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. Canada Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Europe Pril-series Drugs API Sales Market Share by Country (2021–2032)
 Figure 31. Europe Pril-series Drugs API Revenue Market Share by Country (2021–2032)
 Figure 32. Germany Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. France Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. U.K. Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Italy Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. Russia Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. Asia Pacific Pril-series Drugs API Sales Market Share by Region (2021–2032)
 Figure 38. Asia Pacific Pril-series Drugs API Revenue Market Share by Region (2021–2032)
 Figure 39. China Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Japan Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. South Korea Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. India Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Australia Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. China Taiwan Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Southeast Asia Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Latin America Pril-series Drugs API Sales Market Share by Country (2021–2032)
 Figure 47. Latin America Pril-series Drugs API Revenue Market Share by Country (2021–2032)
 Figure 48. Mexico Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Brazil Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Argentina Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Colombia Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Middle East and Africa Pril-series Drugs API Sales Market Share by Country (2021–2032)
 Figure 53. Middle East and Africa Pril-series Drugs API Revenue Market Share by Country (2021–2032)
 Figure 54. Turkey Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Saudi Arabia Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. UAE Pril-series Drugs API Revenue Growth Rate (US$ Million), 2021–2032
 Figure 57. Global Sales Market Share of Pril-series Drugs API by Type (2021–2032)
 Figure 58. Global Revenue Market Share of Pril-series Drugs API by Type (2021–2032)
 Figure 59. Global Pril-series Drugs API Price (US$/Kg) by Type (2021–2032)
 Figure 60. Global Sales Market Share of Pril-series Drugs API by Application (2021–2032)
 Figure 61. Global Revenue Market Share of Pril-series Drugs API by Application (2021–2032)
 Figure 62. Global Pril-series Drugs API Price (US$/Kg) by Application (2021–2032)
 Figure 63. Pril-series Drugs API Value Chain
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Leap India